SG11201906778RA - Improved methods for assessing risk of developing breast cancer - Google Patents

Improved methods for assessing risk of developing breast cancer

Info

Publication number
SG11201906778RA
SG11201906778RA SG11201906778RA SG11201906778RA SG11201906778RA SG 11201906778R A SG11201906778R A SG 11201906778RA SG 11201906778R A SG11201906778R A SG 11201906778RA SG 11201906778R A SG11201906778R A SG 11201906778RA SG 11201906778R A SG11201906778R A SG 11201906778RA
Authority
SG
Singapore
Prior art keywords
international
risk
breast cancer
victoria
pct
Prior art date
Application number
SG11201906778RA
Other languages
English (en)
Inventor
Richard Allman
Original Assignee
Genetic Tech Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017900208A external-priority patent/AU2017900208A0/en
Application filed by Genetic Tech Limited filed Critical Genetic Tech Limited
Publication of SG11201906778RA publication Critical patent/SG11201906778RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/20—Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medical Informatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Data Mining & Analysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Databases & Information Systems (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Molecular Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biomedical Technology (AREA)
  • Primary Health Care (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)
  • Oncology (AREA)
  • Evolutionary Computation (AREA)
  • Software Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG11201906778RA 2017-01-24 2018-01-23 Improved methods for assessing risk of developing breast cancer SG11201906778RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2017900208A AU2017900208A0 (en) 2017-01-24 Improved methods for assessing risk of developing breast cancer
PCT/AU2018/050041 WO2018136995A1 (en) 2017-01-24 2018-01-23 Improved methods for assessing risk of developing breast cancer

Publications (1)

Publication Number Publication Date
SG11201906778RA true SG11201906778RA (en) 2019-08-27

Family

ID=62977826

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201906778RA SG11201906778RA (en) 2017-01-24 2018-01-23 Improved methods for assessing risk of developing breast cancer

Country Status (10)

Country Link
US (1) US20200102617A1 (de)
EP (1) EP3574113A4 (de)
JP (1) JP2020508643A (de)
KR (1) KR20190110594A (de)
CN (1) CN110382712A (de)
AU (1) AU2018213400A1 (de)
CA (1) CA3051488A1 (de)
IL (1) IL268235A (de)
SG (1) SG11201906778RA (de)
WO (1) WO2018136995A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015327756B2 (en) 2014-09-30 2018-01-04 Genetic Technologies Limited Methods for assessing risk of developing breast cancer
EP3839974B9 (de) * 2019-12-20 2023-05-03 Dynamic Code AB Verfahren zur analyse der wahrscheinlichkeit von krankheiten
EP4053853A1 (de) * 2021-03-01 2022-09-07 ScreenPoint Medical B.V. Gerät zur bestimmung eines zeitlichen brustkrebsrisikos
CN114283883B (zh) * 2021-12-27 2022-11-22 上海华测艾普医学检验所有限公司 基于分子标记的用于肝癌筛查和风险预测的系统及应用
CN115424669B (zh) * 2022-08-18 2023-06-13 南方医科大学南方医院 一种基于lr评分的三阴性乳腺癌疗效及预后评估模型

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2896881B1 (fr) * 2006-01-31 2008-04-18 Biomerieux Sa Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie
EP2313525A2 (de) * 2008-07-07 2011-04-27 Decode Genetics EHF Genetische varianten zur beurteilung des brustkrebsrisikos
MX2011012913A (es) * 2009-06-01 2012-02-21 Genetic Technologies Ltd Métodos para evaluar el riesgo de cáncer de mama.
AU2015327756B2 (en) * 2014-09-30 2018-01-04 Genetic Technologies Limited Methods for assessing risk of developing breast cancer
EP3695015A4 (de) * 2017-10-13 2021-07-07 Genetic Technologies Limited Verfahren zur beurteilung des risikos des auftretens von brustkrebs

Also Published As

Publication number Publication date
IL268235A (en) 2019-09-26
WO2018136995A1 (en) 2018-08-02
KR20190110594A (ko) 2019-09-30
JP2020508643A (ja) 2020-03-26
EP3574113A1 (de) 2019-12-04
US20200102617A1 (en) 2020-04-02
CA3051488A1 (en) 2018-08-02
AU2018213400A1 (en) 2019-08-22
CN110382712A (zh) 2019-10-25
EP3574113A4 (de) 2020-10-28

Similar Documents

Publication Publication Date Title
SG11201910019PA (en) Microorganisms and methods for producing cannabinoids and cannabinoid derivatives
SG11201906778RA (en) Improved methods for assessing risk of developing breast cancer
SG11201907912YA (en) An appliance operation signal processing system and method
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201805906WA (en) Diagnostic and prognostic methods for cardiovascular diseases and events
SG11201804758QA (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11201809252YA (en) Methods for determining dpp3 and therapeutic methods
SG11201908238SA (en) Anti-c5 antibodies and uses thereof
SG11201908743SA (en) Methods and compositions for modulation of immune cells
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201806432PA (en) Methods for assessing risk of developing colorectal cancer
SG11201808762XA (en) Diagnostic methods for patient specific therapeutic decision making in cancer care
SG11201910195WA (en) Methods for trapping and barcoding discrete biological units in hydrogel
SG11201907208XA (en) Radiolabeled anti-lag3 antibodies for immuno-pet imaging
SG11201909064RA (en) Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
SG11201907927SA (en) Binding molecules that specifically bind to tau
SG11201909807TA (en) Methods of manufacturing of niraparib
SG11201807062RA (en) Anti-tnfalpha-antibodies and functional fragments thereof
SG11201910206QA (en) Methods and compositions for treating inflammatory gastrointestinal disorders
SG11201809793UA (en) Tl1a antibodies and uses thereof
SG11201908275XA (en) Peptides and methods for the treatment of diabetes
SG11201906313SA (en) A polypeptide linker for preparing multispecific antibodies